ClinicalTrials.gov record
Completed Phase 1 Interventional

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

ClinicalTrials.gov ID: NCT03748186

Public ClinicalTrials.gov record NCT03748186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Study identification

NCT ID
NCT03748186
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Sutro Biopharma, Inc.
Industry
Enrollment
136 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2019
Primary completion
Jun 3, 2024
Completion
Jun 3, 2024
Last update posted
Aug 19, 2025

2019 – 2024

United States locations

U.S. sites
23
U.S. states
19
U.S. cities
22
Facility City State ZIP Site status
Arizona Oncology - Tucson Tucson Arizona 85711
UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit Los Angeles California 90095
Sutter Health- Palo Alto Medical Foundation San Francisco California 94109
Rocky Mountain Cancer Center Aurora Colorado 80012
Yale School of Medicine New Haven Connecticut 06520
Miami Cancer Institue, Baptist Health South Florida Miami Florida 33176
University of South Florida Tampa Florida 33606
Augusta Oncology Augusta Georgia 30912
University of Chicago Chicago Illinois 60637
Maryland Oncology Hematology Rockville Maryland 20850
Minnesota Oncology Hematology Minneapolis Minnesota 55404
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
NYU Langone Medical Center New York New York 10016
Levine Cancer Institute Charlotte North Carolina 28204
University of Cincinnati Cancer Institute Cincinnati Ohio 45267
Ohio State University, James Cancer Center Columbus Ohio 43210
University of Pennsylvania Philadelphia Pennsylvania 19104
Thomas Jefferson University Philadelphia Pennsylvania 19107
Prisma Health Greenville South Carolina 29605
Sarah Cannon Research Institute Nashville Tennessee 37203
Virginia Cancer Specialists Fairfax Virginia 22031
Cancer Care Northwest-South Spokane Spokane Washington 99204
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03748186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2025 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03748186 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →